In summary, the UBS analyst reiterated the Buy rating for Cigna stock, with a steady price target of $390.00. ... which includes detailed analysis of the company’s valuation, growth prospects, ...

Rice provided insights following a recent investor event at the Evernorth Innovation Lab, hosted alongside Cigna management. According to InvestingPro data, the company currently trades at $315.99, ...

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated ...

Hims & Hers Health, Inc. navigates strong growth and partnerships despite rising competitive risks. Click here to read an analysis of HIMS stock now.

Active large-cap mutual-fund managers have bigger relative positions in financials such as Wells Fargo and BofA than big tech ...

As Trump's sweeping tax-cut and spending bill marches forward, analysts examine how his broad-ranging policies could turn the ...

In Medicare Advantage, UnitedHealth holds a firm advantage, having increased its market share from 25% in 2017 to 29% in 2023. For comparison, Humana (NYSE: HUM) holds 18% market share in both periods ...

The cost of similar Covid-19 treatments can vary by tens of thousands of dollars a patient, even within the same hospital, according to a Wall Street Journal analysis of pricing data that ...

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Hims & Hers Health? Access our full analysis report here ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.3% in the afternoon session after Cigna Group's Evernorth ...

Sector peers Cigna (CI), CVS Health (CVS), and Humana (HUM) are all deep in the red in response to today's news. This is poised to be the stock's sixth ... intraday analysis and 43+ years of ...